• CareDx closed the sale of its Lab Products business to Eurobio Scientific on June 30, 2026.
• Received $171.2 million in cash at closing, subject to customary post-closing adjustments.
• Deal shifts focus to U.S. precision medicine testing services, patient solutions, digital offerings; operating model simplified.
• Additional financial impact, including pro forma results, expected on the second-quarter 2026 earnings call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.